Cite
Sievers P, Stichel D, Sill M, et al. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathol. 2021;142(6):1065-1069doi: 10.1007/s00401-021-02369-1.
Sievers, P., Stichel, D., Sill, M., Schrimpf, D., Sturm, D., Selt, F., Ecker, J., Kazdal, D., Miele, E., Kranendonk, M. E. G., Tops, B. B. J., Kohlhof-Meinecke, P., Beschorner, R., Kramm, C. M., Hasselblatt, M., Reifenberger, G., Capper, D., Wesseling, P., Stenzinger, A., Milde, T., Korshunov, A., Witt, O., Pfister, S. M., Wick, W., von Deimling, A., Jones, D. T. W., & Sahm, F. (2021). GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta neuropathologica, 142(6), 1065-1069. https://doi.org/10.1007/s00401-021-02369-1
Sievers, Philipp, et al. "GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types." Acta neuropathologica vol. 142,6 (2021): 1065-1069. doi: https://doi.org/10.1007/s00401-021-02369-1
Sievers P, Stichel D, Sill M, Schrimpf D, Sturm D, Selt F, Ecker J, Kazdal D, Miele E, Kranendonk MEG, Tops BBJ, Kohlhof-Meinecke P, Beschorner R, Kramm CM, Hasselblatt M, Reifenberger G, Capper D, Wesseling P, Stenzinger A, Milde T, Korshunov A, Witt O, Pfister SM, Wick W, von Deimling A, Jones DTW, Sahm F. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathol. 2021 Dec;142(6):1065-1069. doi: 10.1007/s00401-021-02369-1. Epub 2021 Sep 18. PMID: 34536122; PMCID: PMC8568855.
Copy
Download .nbib